For diabetes patients, healthcare providers, and diagnostic laboratories, regular blood sampling is essential for monitoring chronic conditions. Traditional blood collection methods (fingersticks) require safe, pain-minimizing, and easy-to-use devices. The solution is Lancets—a pricking needle used to obtain drops of blood for testing. Lancets are designed to be used once and disposed of safely. These devices are used for cholesterol and glucose tests, heelstick screening tests or phenylketonuria (PKU) tests in newborns, as well as for severely burned or scarred emergency patients, extremely obese patients, and thrombotic-tendency patients. This report analyzes this mature blood sampling segment, projected to grow at 3.0% CAGR through 2031.
According to the latest release from global leading market research publisher QYResearch, *”Lancets – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032,”* the global market for Lancets was valued at US$ 1,673 million in 2024 and is forecast to reach US$ 2,056 million by 2031, representing a compound annual growth rate (CAGR) of 3.0% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4937609/lancets
Product Definition – Types and Applications
Lancets are pricking needles used to obtain drops of blood for testing. Lancets are designed to only be used once, then disposed of safely. These devices are used for cholesterol and glucose tests, heelstick screening tests or PKU tests in newborns, as well as for severely burned or scarred emergency patients, extremely obese patients, and thrombotic-tendency patients.
Core Types:
Safety Lancets (60-65% of market, fastest-growing at 4-5% CAGR): Single-use, pre-loaded spring mechanism. Needle retracts automatically after use (prevents needle stick injuries). No visible needle before or after use. Higher cost (US$ 0.10-0.30 per unit). Preferred in hospitals and clinics (infection control). Growing due to safety regulations (OSHA, EU directives).
Ordinary Lancets (35-40% of market): Simple needle without safety mechanism. Lower cost (US$ 0.02-0.10 per unit). Used with separate lancing device. Needle visible after use (sharps disposal required). Used in home settings (cost-sensitive patients). Declining share as safety lancets become more affordable.
Key Applications:
Blood Glucose Test (70-75% of market, largest segment): Diabetes patients test blood sugar multiple times daily (type 1: 4-10 times/day; type 2 on insulin: 2-4 times/day; type 2 not on insulin: 1-2 times/day). Each test requires one lancet. Global diabetes prevalence: 537 million adults (2024), projected 783 million by 2045. Growing at 3-4% CAGR.
Newborn Screening (10-15% of market): Heelstick blood samples for metabolic disorders (PKU, hypothyroidism, sickle cell disease). Required for all newborns in developed countries (99%+ screening rate). Stable demand tied to birth rates.
Rapid Blood Test (5-10% of market): Point-of-care testing (cholesterol, hemoglobin A1c, infectious diseases). Hospital emergency departments, urgent care centers, physician offices.
Other (5-10% of market): Veterinary use, research, home diagnostics.
Production Economics (2024 Data): Global production reached approximately 55.37 billion units, with an average global market price of around US$ 30.22 per thousand units (US$ 0.030 per lancet). At 55 billion units, the market is massive in volume but low in unit value.
Key Industry Characteristics
Characteristic 1: Diabetes Prevalence as Primary Demand Driver
The rise in chronic conditions like diabetes, which require regular blood glucose monitoring, is a significant driver for lancet demand. As the number of diabetes patients increases globally (537 million → 783 million by 2045), the need for lancets continues to grow. Each lancet is single-use, creating recurring demand. Unlike glucose strips (which compete with continuous glucose monitors), lancets have fewer alternatives (no non-invasive option with equivalent cost). Home-based healthcare and self-monitoring trends have driven use of lancets, allowing patients to monitor health conveniently and cost-effectively.
Characteristic 2: Technological Advancements Improving User Experience
Innovations such as ultra-thin needles (30-33 gauge vs. 21-25 gauge standard), painless lancet designs (vibration-assisted, silicone-coated), and easy-to-use lancet devices improve user experience, making blood sampling more comfortable and encouraging more frequent use. Pain reduction is critical for patient compliance (40% of diabetes patients report testing less frequently due to pain). Premium lancets (US$ 0.10-0.30) offer 30-50% less pain than standard lancets (US$ 0.02-0.05).
Characteristic 3: Competition from Alternative Technologies
Non-invasive blood glucose monitoring methods (continuous glucose monitors (CGM) or sensor-based systems) are gaining traction, potentially reducing reliance on traditional lancets for blood sampling. CGM (Dexcom, Abbott Freestyle Libre, Medtronic) reduces fingerstick frequency (calibration required 0-2 times daily vs. 4-10 times for traditional glucose monitoring). However, CGM is more expensive (US$ 1,000-2,000/year vs. US$ 100-200/year for lancets + strips). CGM penetration is 10-15% of type 1 diabetes, 2-5% of type 2. Lancets remain standard for most patients, especially in developing countries.
Characteristic 4: Competitive Landscape – Global Healthcare Giants
Key players include Roche (Switzerland – Accu-Chek brand, lancets and lancing devices), Lifescan (US – OneTouch brand), BD (US – largest needle/syringe manufacturer), MTD Group, Greiner Bio One (Austria – blood collection), Owen Mumford (UK – Unistik safety lancets), Cardinal Health (US – distribution), Ascensia (US – Contour brand), Abbott (US – FreeStyle brand), B. Braun (Germany), Terumo (Japan), I-SENS (Korea), Nipro (Japan), ICU Medical (US), Sarstedt (Germany), Sinocare (China – domestic leader), Yueyue Medical (China), Tianjin Huahong Medical (China), Suzhou Shilai Medical (China), Shandong Lianfa Medical (China), Promisemed (China). The market is fragmented (top 5 players account for 30-35% of revenue). Roche, BD, and Lifescan are global leaders. Chinese manufacturers dominate domestic market with lower-cost products (US$ 0.01-0.02 per lancet vs. US$ 0.03-0.05 for global brands).
Exclusive Analyst Observation – The Safety Lancet Regulatory Push: Needle stick injuries affect 600,000-800,000 healthcare workers annually (WHO). Safety lancets (automatic retraction) reduce injury risk by 80-90%. OSHA (US) and EU directives mandate safety-engineered devices for healthcare settings. Hospitals have nearly 100% safety lancet adoption. Home use is still mostly ordinary lancets (cost-sensitive). As safety lancet prices decline (US$ 0.10 → US$ 0.05 in past 5 years), home adoption is increasing. Safety lancets are growing at 4-5% CAGR vs. 1-2% for ordinary lancets.
User Case Example – Diabetes Patient Home Monitoring (2025)
A type 2 diabetes patient (non-insulin, 2 tests/day) uses ordinary lancets (US$ 0.03/unit) with a lancing device. Annual lancet cost: 730 units × US$ 0.03 = US$ 22. Patient reports occasional pain (30% of tests) but tolerates due to low cost. Switching to safety lancets (US$ 0.12/unit) would cost US$ 88/year (4x higher). Patient prefers ordinary lancets for cost savings. This case illustrates the cost sensitivity of home users (source: patient survey, 2025).
Technical Pain Points and Recent Innovations
Pain and Patient Compliance: Needle gauge affects pain (higher gauge = thinner = less pain). 30-33 gauge (0.30-0.23 mm diameter) vs. 21-25 gauge (0.51-0.31 mm). Blood volume decreases with higher gauge (may require deeper puncture). Recent innovation: Silicone-coated needles (reduce friction), vibration-assisted lancets (distract pain sensation), and adjustable depth settings (customize for skin thickness).
Infection Risk from Improper Disposal: Used lancets are sharps waste (needlestick injury risk). Recent innovation: Integrated sharps containers (lancet clicks into disposal container). Safety lancets (needle never exposed). Reuse prevention mechanisms (cannot be activated twice). Patient education on safe disposal.
Environmental Concerns: 55 billion lancets annually = 1,000+ tons of medical waste. Recent innovation: Biodegradable lancets (plant-based plastics). Recycling programs (not widespread). Regulatory pressure may increase (EU Medical Device Regulation).
Recent Policy Driver – EU Medical Device Regulation (MDR) (fully enforced 2025): Lancets are Class I medical devices (low risk). MDR requires clinical evaluation, post-market surveillance, and UDI (unique device identification). Compliance costs increased 20-30% for manufacturers. Some small players exited EU market, reducing competition and stabilizing prices.
Segmentation Summary
Segment by Type: Safety Lancets (60-65% of market) – automatic retraction, higher cost, fastest-growing (4-5% CAGR). Ordinary Lancets (35-40%) – simple needle, lower cost, declining share.
Segment by Application: Blood Glucose Test (70-75% of market) – diabetes monitoring, largest segment. Newborn Screening (10-15%) – heelstick tests, stable demand. Rapid Blood Test (5-10%) – point-of-care testing. Other (5-10%) – veterinary, research.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
